The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer.

Autor: Roeland EJ; Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA., Fintelmann FJ; Department of Radiology, Massachusetts General Hospital, Boston, MA, USA., Hilton F; Pfizer Inc., Groton, CT, USA., Yang R; Pfizer Inc., New York, NY, USA., Whalen E; Pfizer Inc., New York, NY, USA., Tarasenko L; Pfizer Inc., New York, NY, USA., Calle RA; Pfizer Worldwide Research and Development, Cambridge, MA, USA., Bonomi PD; Rush University Medical Center, Chicago, IL, USA.
Jazyk: angličtina
Zdroj: Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2024 Jun; Vol. 15 (3), pp. 1030-1040. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1002/jcsm.13426
Abstrakt: Background: This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy.
Methods: Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.0%. Cox proportional hazard modelling of OS was used to estimate hazard ratios (HRs) for each category, including baseline covariates, time to weight gain, and time to confirmed objective response (RECIST Version 1.0).
Results: Of 1030 patients with advanced NSCLC (IIIB 11.5% and IV 88.5%), 453 (44.0%), 252 (24.5%), and 120 (11.7%) experienced weight gain from baseline of >0%, >2.5%, and >5.0%, respectively. The median time to weight gain was 23 (>0%), 43 (>2.5%), and 45 (>5.0%) days. After adjusting for a time-dependent confirmed objective response, the risk of death was reduced for patients with any weight gain (>0% vs. ≤0% [HR 0.71; 95% confidence interval-CI 0.61, 0.82], >2.5% vs. ≤2.5% [HR 0.76; 95% CI 0.64, 0.91] and >5.0% vs. ≤5.0% [HR 0.77; 95% CI 0.60, 0.99]). The median OS was 13.5 versus 8.6 months (weight gain >0% vs. ≤0%), 14.4 versus 9.4 months (weight gain >2.5% vs. ≤2.5%), and 13.4 versus 10.2 months (weight gain >5.0% vs. ≤5.0%).
Conclusions: Weight gain during treatment was associated with a reduced risk of death, independent of tumour response. The survival benefit was comparable for weight gain >0%, >2.5%, and >5.0%, suggesting that any weight gain may be an early predictor of survival with implications for the design of interventional cancer cachexia studies.
(© 2024 Pfizer Inc. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.)
Databáze: MEDLINE